Phase 2 Lung Cancer Trial, Recruiting NCT06311981 Sponsor: Jian Chen Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT06311981
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 75 years of age.
  • People with a general health and activity level that falls within a certain range, meaning they are able to carry out some daily activities, even if limited (this is measured using a standard scale called the ECOG score of 0–2; confirm with trial site if unsure where someone falls on this scale).
  • People who have been diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC), confirmed through a tissue or cell sample, at a stage that has not spread to distant parts of the body (stages IIb–IIIc).
  • People whose cancer cannot be safely treated with surgery, or who have chosen not to have surgery.
  • People whose blood counts, lung function, heart function, liver function, and kidney function all meet certain minimum levels as assessed by a doctor (confirm with trial site for specific values).
  • People who are able and willing to give written informed consent to participate.

Who may not be able to join:

  • People with squamous cell carcinoma (a specific type of non-small cell lung cancer) who have previously been treated with a drug called bevacizumab before receiving carbon ion radiotherapy.
  • People who have another active cancer that has not been controlled.
  • People whose radiation treatment plan cannot safely cover the tumour or adequately protect surrounding healthy tissue and organs.
  • People who have previously had radiation therapy to the chest, or have had radioactive seeds implanted in the chest.
  • People who have a cardiac pacemaker or certain metal implants inside their body that could be affected by high-energy radiation or could interfere with treatment planning.
  • People who are HIV positive, are in an active phase of hepatitis virus infection requiring antiviral treatment but are unable to receive it due to other health conditions, or who have active syphilis.
  • People with a history of mental illness that may prevent them from completing the treatment programme.
  • People with serious other health conditions that could interfere with radiotherapy, including: active infections; unstable chest pain, heart failure, or a heart attack within the past 6 months; a flare-up of a lung condition requiring hospitalisation; severely weakened immune function; conditions that cause extreme sensitivity to radiation (such as ataxia telangiectasia); or other conditions a doctor considers incompatible with this type of treatment.
  • People whom the treating doctor considers unsuitable for participation in the study for other reasons.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jingfang Mao, PHD, Shanghai Proton and Heavy Ion Center

Phone: 86-21-38296678

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Jian Chen
Registry
ClinicalTrials.gov
Start date
8 August 2024
Est. completion
17 June 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Disease progression-free survival rate; Incidence of Treatment-induced Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov